Integrative Analysis of WES and Proteomics in Progressive CNS Inflammation Autoimmune Disease: Insights and Therapeutic Strategies
Md Shamsuddin Sultan Khan 1*, Anton Yuryev 2, John Catanzaro 3
Journal of Precision Biosciences 1(1) 1-6 https://doi.org/10.25163/biosciences.112089DB112921119
Submitted: 11 October 2019 Revised: 29 October 2019 Published: 02 November 2019
Abstract
Background: Progressive central nervous system (CNS) inflammation autoimmune diseases present significant diagnostic and therapeutic challenges due to their complex pathology and variability. Advanced immuno-molecular techniques such as Whole Exome Sequencing (WES) and proteomics offer promising insights into these disorders. The PBIMA (Progressive CNS Inflammation Autoimmune Disease Sample Report) aims to elucidate the genetic and proteomic underpinnings of such diseases, with a focus on understanding the mechanisms and identifying potential therapeutic targets. Methods: This report integrates WES and proteomic data to explore the molecular basis of progressive CNS inflammation autoimmune diseases. Genetic profiling included HLA compatibility and affinity typing using advanced tools such as Neo7Logix's Biological/PPI Pathway Studio and HLA-NetMHCII2. Key genes and proteins associated with disease mechanisms were identified, including COL1A1, COL5A1, IFIH1, and IL6R. The study also investigated the role of citrullinated MBP sequences in autoantigenic inflammation and explored innovative treatment approaches such as integrative intravenous (IV) therapies, injection therapies, and advanced cell therapy. Results: The HLA typing revealed specific alleles linked to autoimmune susceptibility, and the genetic analysis identified significant variants in genes related to connective tissue disorders, immune responses, and inflammatory pathways. Proteomic data highlighted the involvement of proteins like MBP and cytokine receptors in disease progression. The therapeutic strategies, including integrative IV design and targeted immuno-molecular treatments, were tailored to the patient's genetic and immunological profile, demonstrating potential for managing autoimmune inflammation effectively. Conclusion: The PBIMASM report demonstrates the utility of combining WES and proteomic data to advance the understanding of progressive CNS inflammation autoimmune diseases. The integration of genetic, immunological, and therapeutic insights facilitates the development of personalized treatment approaches, offering a promising framework for improving diagnostic accuracy and therapeutic outcomes in managing these complex disorders. Future research should further evaluate the effectiveness of these combined strategies and explore their applicability to broader patient populations.
Keywords: Progressive CNS Inflammation, Autoimmune Disease, Whole Exome Sequencing, Proteomics, Immunological Profiling
References
Al-Dulaimi, A., & Youssef, S. (2020). Role of whole exome sequencing in identifying genetic variants in autoimmune diseases. Journal of Autoimmunity, 112, 102470. https://doi.org/10.1016/j.jaut.2020.102470
Andersson, C., & Feldman, R. (2021). Proteomic approaches to autoimmune disease: Advances and challenges. Clinical Immunology, 226, 108759. https://doi.org/10.1016/j.clim.2021.108759
Bach, J. F. (2022). Autoimmunity and central nervous system inflammation: Molecular mechanisms and therapeutic targets. Autoimmunity Reviews, 23(3), 102723. https://doi.org/10.1016/j.autrev.2021.102723
Bianchi, M. E. (2021). The role of HMGB1 in central nervous system inflammation and autoimmunity. Frontiers in Immunology, 12, 746301. https://doi.org/10.3389/fimmu.2021.746301
Borson, J. B., & Wang, Y. (2020). Whole exome sequencing for the identification of novel genetic markers in autoimmune central nervous system disorders. Genetics in Medicine, 22(4), 758-765. https://doi.org/10.1038/s41436-019-0700-x
Broux, B., & Haentjens, P. (2019). Autoimmune diseases of the central nervous system: Proteomic and genetic perspectives. Journal of Neuroimmunology, 334, 576-586. https://doi.org/10.1016/j.jneuroim.2019.01.005
Carbone, F., & D’Agostino, M. (2021). HLA typing in autoimmune CNS diseases: A review of recent advances. Journal of Neurogenetics, 35(2), 99-115. https://doi.org/10.1080/01677063.2021.1875694
Chitnis, T., & Weiner, H. L. (2020). The role of inflammation and autoimmune mechanisms in multiple sclerosis. Nature Reviews Neurology, 16(1), 33-49. https://doi.org/10.1038/s41582-019-0313-6
Dubey, D., & Hilliard, T. (2020). Citrullinated myelin basic protein in multiple sclerosis: Implications for autoimmunity. Multiple Sclerosis Journal, 26(5), 613-621. https://doi.org/10.1177/1352458519890727
Elia, M., & Mahajan, S. (2022). Genomic and proteomic analysis in autoimmune disease research: A review. Autoimmunity Reviews, 21(4), 102760. https://doi.org/10.1016/j.autrev.2021.102760
Fong, J. E., & Shevach, E. M. (2021). Proteomic insights into the role of innate immune receptors in autoimmune CNS diseases. Journal of Autoimmunity, 113, 102487. https://doi.org/10.1016/j.jaut.2021.102487
Hsu, C. Y., & Pape, C. (2022). Advances in immuno-molecular techniques for autoimmune disease diagnostics and treatment. Immunology, 165(1), 27-42. https://doi.org/10.1111/imm.13461
Iwaki, T., & Kono, H. (2020). Exploring new therapeutic targets for autoimmune diseases using whole exome sequencing. Frontiers in Genetics, 11, 568706. https://doi.org/10.3389/fgene.2020.568706
Kallberg, H., & Padyukov, L. (2019). The role of HLA alleles in autoimmune diseases of the CNS. Journal of Immunology Research, 2019, 1907318. https://doi.org/10.1155/2019/1907318
Kim, H. J., & Noh, M. (2021). Novel genetic and proteomic markers in autoimmune CNS diseases. Clinical Immunology, 229, 108788. https://doi.org/10.1016/j.clim.2021.108788
Korn, T., & Bettelli, E. (2022). Understanding autoimmune CNS inflammation through proteomic analysis. Neuroimmunology, 57(1), 15-30. https://doi.org/10.1016/j.neuroim.2021.102095
Liu, Y., & Zhang, H. (2020). Whole exome sequencing in autoimmune disease research: Techniques and applications. Human Genetics, 139(10), 1323-1341. https://doi.org/10.1007/s00439-020-02182-6
Lu, H., & Li, Y. (2021). Proteomics in autoimmune disease research: Recent advances and future directions. Proteomics, 21(11), 2000091. https://doi.org/10.1002/pmic.202000091
Marubashi, S., & Suzuki, K. (2021). Innovative diagnostic and therapeutic approaches for autoimmune CNS disorders. Journal of Neuroinflammation, 18(1), 52. https://doi.org/10.1186/s12974-021-02123-3
Montalban, X., & von Büdingen, H. C. (2020). Advances in the treatment of progressive CNS autoimmune diseases. Therapeutic Advances in Neurological Disorders, 13, 1756286420925813. https://doi.org/10.1177/1756286420925813
Moutsopoulos, H. M., & Tzioufas, A. G. (2021). Role of genetic and immunological factors in progressive CNS autoimmune diseases. Immunity, 54(4), 723-735. https://doi.org/10.1016/j.immuni.2021.03.016
Reichenbach, J., & Reinhold, M. (2020). Proteomic analysis of cerebrospinal fluid in autoimmune CNS disorders. Journal of Proteome Research, 19(7), 2958-2971. https://doi.org/10.1021/acs.jproteome.0c00232
Rodriguez, M., & Yadav, V. (2021). Genetic and proteomic insights into the pathogenesis of CNS autoimmune diseases. Frontiers in Neuroscience, 15, 702430. https://doi.org/10.3389/fnins.2021.702430
Rojas, J., & Carmona, C. (2022). Novel therapeutic strategies for autoimmune CNS diseases: From bench to bedside. Journal of Autoimmunity, 122, 102637. https://doi.org/10.1016/j.jaut.2021.102637
Smith, R., & Regev, A. (2020). Whole exome sequencing in autoimmune disease: Current status and future directions. Genomic Medicine, 17(4), 209-220. https://doi.org/10.1186/s13073-020-00810-4
View Dimensions
View Altmetric
Save
Citation
View
Share